Background/Objective: The management of chronic childhood idiopathic thrombocytopenic purpura (ITP) is distinct from acute ITP. Similar to the publication on acute ITP guidelines, the AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica) considered it appropriate to develop consensus guidelines for chronic childhood ITP to provide useful and shared information for physicians, healthcare professionals, parents and patients. Design/Methods: A preliminary, evidence-based document issued by a select group of AIEOP pediatric hematologists was discussed, modified and approved during a Consensus Conference according to procedures previously validated by the AIEOP Board. Results: The guidelines give prominence to the periodical reevaluation of all the etiological hypotheses of thrombocytopenia in relation to its clinical condition. The majority of chronic ITP children do not require treatment, especially if bleeding is absent or minimal. The treatment decision depends on several factors other than the platelet count, and treatment options are suggested in relation to the therapeutic scenarios. Recommendations are given regarding support for surgery, particular hemorrhagic conditions, daily activities/sports, as well as for vaccines and drugs. Experimental treatments are also discussed.

Keywords:
Idiopathic thrombocytopenic purpura, Management of pediatric thrombocytopenia, Pediatric thrombocytopenia, Platelet count, Thrombocytopenia
1.
Del Vecchio GC, De Santis A, Giordano P, Amendola G, Baronci C, Del Principe D, Nobili B, Jankovich M, Ramenghi U, Russo G, Zecca M, De Mattia D, AIEOP ITP Study Group: Management of acute childhood idiopathic thrombocytopenic purpura according to AIEOP consensus guidelines: assessment of Italian experience. Acta Haematol 2008;119:1–7.
2.
De Mattia D, Del Principe D, Del Vecchio GC, Jankovic M, Arrighini A, Giordano P, Menichelli A, Mori P, Zecca M, Pession A: Acute childhood idiopathic thrombocytopenic purpura: AIEOP consensus guidelines for diagnosis and treatment. Haematologica 2000;85:420–424.
3.
Imbach P: Immune thrombocytopenia; in Lilleyman JS, Hann IM, Blanchette VS (eds): Pediatric Hematology, ed 2. London, Churchill Livingstone 1999, p 437.
4.
Dickerhoff R, von Ruecker A: The clinical course of immune thrombocytopenic purpura in children who did not receive intravenous immunoglobulins or sustained prednisone treatment. J Pediatr 2000;137:629–632.
5.
Kühne T, Imbach P, Bolton-Maggs PH, Berchtold W, Blanchette V, Buchanan GR, Intercontinental Childhood ITP Study Group: Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet 2001;358:2122–2125.
6.
Rosthøj S, Hedlund-Treutiger I, Rajantie J, Zeller B, Jonsson OG, Elinder G, Wesenberg F, Henter JI, NOPHO ITP Working Group: Duration and morbidity of newly diagnosed idiopathic thrombocytopenic purpura in children: a prospective Nordic study of an unselected cohort. J Pediatr 2003;143:302–307.
7.
Kühne T, Buchanan GR, Zimmerman S, Michaels LA, Kohan R, Berchtold W, Imbach P, Intercontinental Childhood ITP Study Group: A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr 2003;143:605–608.
8.
Watts RG: Idiopathic thrombocytopenic purpura: a 10-year natural history study at the Childrens Hospital of Alabama. Clin Pediatr (Phila) 2004;43:691–702.
9.
Lowe EJ, Buchanan GR: Idiopathic thrombocytopenic purpura diagnosed during the second decade of life. J Pediatr 2002;141:253–258.
10.
Jayabose S, Levendoglu-Tugal O, Ozkaynkak MF, Visintainer P, Sandoval C: Long-term outcome of chronic idiopathic thrombocytopenic purpura in children. J Pediatr Hematol Oncol 2004;26:724–726.
11.
Reid MM: Chronic idiopathic thrombocytopenic purpura: incidence, treatment, and outcome. Arch Dis Child 1995;72:125–128.
12.
Aronis S, Platokouki H, Mitsika A, Haidas S, Costantopoulos A: Seventeen years of experience with chronic idiopathic thrombocytopenic purpura in childhood. Is therapy always better? Pediatr Hematol Oncol 1994;11:487–498.
13.
Bader-Meunier B, Proulle V, Trichet C, Debray D, Gabolde M, Yvart J, Dreyfus M: Misdiagnosis of chronic thrombocytopenia in childhood. J Pediatr Hematol Oncol 2003;25:548–552.
14.
Noris P, Pecci A, Di Bari F, Di Stazio MT, Di Pumpo M, Ceresa IF, Arezzi N, Ambaglio C, Savoia A, Balduini CL: Application of a diagnostic algorithm for inherited thrombocytopenias to 46 consecutive patients. Haematologica 2004;89:1219–1225.
15.
Balduini CL, Cattaneo M, Fabris F, Gresele P, Iolascon A, Pulcinelli FM, Savoia A, Italian Gruppo di Studio delle Piastrine: Inherited thrombocytopenias: a proposed diagnostic algorithm from the Italian Gruppo di Studio delle Piastrine. Haematologica 2003;88:582–592.
16.
Ho CY, Otterud B, Legare RD, Varvil T, Saxena R, DeHart DB, Kohler SE, Aster JC, Dowton SB, Li FP, Leppert M, Gilliland DG: Linkage of a familial platelet disorder with a propensity to develop myeloid malignancies to human chromosome 21q22.1–22.2. Blood 1996;87:5218–5224.
17.
Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, Ratajczak J, Resende IC, Haworth C, Hock R, Loh M, Felix C, Roy DC, Busque L, Kurnit D, Willman C, Gewirtz AM, Speck NA, Bushweller JH, Li FP, Gardiner K, Poncz M, Maris JM, Gilliland DG: Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999;23:166–175.
18.
Drachman JG: Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood 2004;103:390–398.
19.
Cines DB, Bussel JB, McMillan RB, Zehnder JL: Congenital and acquired thrombocytopenia. Hematology Am Soc Hematol Educ Program 2004, pp 390–406.
20.
Thompson AA, Woodruff K, Feig SA, Nguyen LT, Schanen NC: Congenital thrombocytopenia and radio-ulnar synostosis: a new familial syndrome. Br J Haematol 2001;113:866–870.
21.
AIEOP EWOG-MDS: Prospective non-randomized multi-center study for epidemiology and characterization of myelodysplastic syndromes (MDS) and juvenile myelomonocytic leukemia (JMML) in childhood, 2006 (www.aieop.org/stdoc/prot/mds_ewog_protocollo.dpf.pdf).
22.
Kurata Y, Miyagawa S, Kosugi S, Kashiwagi H, Honda S, Mizutani H, Tomiyama Y, Kanayama Y, Matsuzawa Y: High-titer antinuclear antibodies, anti SSA/Ro antibodies and anti-nuclear RNP antibodies in patients with idiopathic thrombocytopenic purpura. Thromb Haemost 1994;71:184–187.
23.
Zimmerman S, Ware R: Clinical significance of the antinuclear antibody test in selected children with idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 1997;19:297–303.
24.
Hazzan R, Mukamel M, Yacobovich J, Yaniv I, Tamary H: Risk factors for future development of systemic lupus erythematosus in children with idiopathic thrombocytopenic purpura. Pediatr Blood Cancer 2006;47(5 suppl):657–659.
25.
Eliakim R, Heyman S, Kornberg A: Celiac disease and keratoconjunctivitis. Occurrence with thrombocytopenic purpura. Arch Intern Med 1982;142:1037.
26.
Mulder CJ, Pena AS, Jansen J, Oosterhuis JA: Celiac disease and geographic (serpiginous) choroidopathy with occurrence of thrombocytopenic purpura. Arch Intern Med 1983;143:842.
27.
Stenhammar L, Ljunggren CG: Thrombocytopenic purpura and coeliac disease. Acta Paediatr Scand 1988;77:764–766.
28.
Fisgin T, Yarali N, Duru F, Usta B, Kara A: Hematologic manifestation of childhood celiac disease. Acta Haematol 2004;111:211–214.
29.
Jaing TH, Yang CP, Hung IJ, Chiu CH, Chang KW: Efficacy of Helicobacter pylori eradication on platelet recovery in children with chronic idiopathic thrombocytopenic purpura. Acta Paediatr 2003;92:1153–1157.
30.
Hayashi H, Okuda M, Aoyagi N, Yoshiyama M, Miyashiro E, Kounami S, Yoshikawa N: Helicobacter pylori infection in children with chronic idiopathic thrombocytopenic purpura. Pediatr Int 2005;47:292–295.
31.
Suzuki T, Matsushima M, Masui A, Watanabe K, Takagi A, Ogawa Y, Shirai T, Mine T: Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura – a randomized controlled trial. Am J Gastroenterol 2005;100:1265–1270.
32.
Fujimura K, Kuwana M, Kurata Y, Imamura M, Harada H, Sakamaki H, Teramura M, Koda K, Nomura S, Sugihara S, Shimomura T, Fujimoto TT, Oyashiki K, Ikeda Y: Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol 2005;81:162–168.
33.
Jaing TH, Tsay PK, Hung IJ, Chiu CH, Yang CP, Huang IA: The role of Helicobacter pylori infection in children with acute immune thrombocytopenic purpura. Pediatr Blood Cancer 2006;47:215–217.
34.
Asahi A, Kuwana M, Suzuki H, Hibi T, Kawakami Y, Ikeda Y: Effects of a Helicobacter pylori eradication regimen on anti-platelet autoantibody response in infected and uninfected patients with idiopathic thrombocytopenic purpura. Haematologica 2006;91:1436–1437.
35.
Suvajdzic N, Stankovic B, Artiko V, Cvejic T, Bulat V, Bakrac M, Colovic M, Obradovic V, Atkinson HD: Helicobacter pylori eradication can induce platelet recovery in chronic idiopathic thrombocytopenic purpura. Platelets 2006;17:227–230.
36.
Stasi R, Rossi Z, Stipa E, Amadori S, Newland AC, Provan D: Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura. Am J Med 2005;118:414–419.
37.
Hashino S, Mori A, Suzuki S, Izumiyama K, Kahata K, Yonezumi M, Chiba K, Kondo T, Ota S, Toyashima N, Kato N, Tanaka J, Imamura M, Asaka M: Platelet recovery in patients with idiopathic thrombocytopenic purpura after eradication of Helicobacter pylori. Int J Hematol 2003;77:188–191.
38.
Hino M, Yamane T, Park K, Takubo T, Ohta K, Kitagawa S, Higuchi K, Arakawa T: Platelet recovery after eradication of Helicobacter pylori in patients with idiopathic thrombocytopenic purpura. Ann Hematol 2003;82:30–32.
39.
Veneri D, Franchini M, Gottardi M, D’Adda M, Ambrosetti A, Krampera M, Zanetti F, Pizzolo G: Efficacy of Helicobacter pylori eradication in raising platelet count in adult patients with idiopathic thrombocytopenic purpura. Haematologica 2002;87:1177–1179.
40.
Kohda K, Kuga T, Kogawa K, Kanisawa Y, Koike K, Kuroiwa G, Hirayama Y, Sato Y, Niitsu Y: Effect of Helicobacter pylori eradication on platelet recovery in Japanese patients with chronic idiopathic thrombocytopenic purpura and secondary autoimmune thrombocytopenic purpura. Br J Haematol 2002;118:584–588.
41.
Emilia G, Longo G, Luppi M, Gandini G, Morselli M, Ferrara L, Amarri S, Cagossi K, Torelli G: Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura. Blood 2001;97:812–814.
42.
Jackson S, Beck PL, Pineo GF, Poon MC: Helicobacter pylori eradication: novel therapy for immune thrombocytopenic purpura? A review of the literature. Am J Hematol 2005;78:142–150.
43.
Franchini M, Veneri D: Helicobacter pylori-associated immune thrombocytopenia. Platelets 2006;17:71–77.
44.
Rajantie J, Klemola T: Helicobacter pylori and idiopathic thrombocytopenic purpura in children. Blood 2003;101:1660.
45.
Kurekci AE, Atay AA, Sarici SU, Ozcan O: Complete platelet recovery after treatment of Helicobacter pylori infection in a child with chronic immune thrombocytopenic purpura: a case report. Pediatr Hematol Oncol 2004;21:593–596.
46.
Dondi E, Rapa A, Boldorini R, Fonio P, Zanetta S, Oderda G: High accuracy of noninvasive tests to diagnose Helicobacter pylori infection in very young children. J Pediatr 2006;149:817–821.
47.
Hino B, Eliakim R, Levine A, Sprecher H, Berkowitz D, Hartman C, Eshach-Adiv O, Shamir R: Comparison of invasive and non-invasive tests diagnosis and monitoring of Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr 2004;39:519–523.
48.
Paimela HM, Oksala NK, Kaariainen IP, Carlson PJ, Kostiala AA, Sipponen PI: Faecal antigen tests in the confirmation of the effect of Helicobacter eradication therapy. Ann Med 2006;38:352–356.
49.
Canales ML, Mauer AM: Sex-linked hereditary thrombocytopenia as a variant of Wiskott-Aldrich syndrome. N Engl J Med 1967;277:899–901.
50.
Villa A, Notarangelo L, Macchi P, Mantuano E, Cavagni G, Brugnoni D, Strina D, Patrosso MC, Ramenghi U, Sacco MG, Ugazio A, Vezzoni P: X-linked thrombocytopenia and Wiskott-Aldrich syndrome are allelic diseases with mutations in the WASP gene. Nat Genet 1995;9:414–417.
51.
Notarangelo LD, Mazza C, Giliani S, D’Aria C, Gandellini F, Ravelli C, Locatelli MG, Nelson DL, Ochs HD, Notarangelo LD: Missense mutations of the WASP gene cause intermittent X-linked thrombocytopenia. Blood 2002;99:2268–2269.
52.
Inoue H, Kurosawa H, Nonoyama S, Imai K, Kumazaki H, Matsunaga T, Sato Y, Sugita K, Eguchi M: X-linked thrombocytopenia in a girl. Br J Haematol 2002;118:1163–1165.
53.
Sindrome di Wiskott-Aldrich e Piastrinopenia X-recessiva. Raccomandazioni per la diagnosi e la terapia. CSS-AIEOP Immunodeficienze Primitive (www.aieop.org/stdoc/raccomandazioni/racc_was_2004.doc).
54.
van den Oudenrijn S, Bruin M, Folman CC, Peters M, Faulkner LB, de Haas M, von dem Borne AE: Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia. Br J Haematol 2000;110:441–448.
55.
Ihara K, Ishii E, Eguchi M, Takada H, Suminoe A, Good RA, Hara T: Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci USA 1999;96:3132–3136.
56.
Ballmaier M, Germeshausen M, Schulze H, Cherkaoui K, Lang S, Gaudig A, Krukemeier S, Eilers M, Strauss G, Welte K: c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 2001;97:139–146.
57.
Germeshausen M, Ballmaier M, Welte K: MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease. Hum Mutat 2006;27:296.
58.
Pemberton LC, Levett D, Skinner R, Hall AG, Hanley JP: Novel mutations in a child with congenital amegakaryocytic thrombocytopenia. Br J Haematol 2006;135:742–743.
59.
Kaito K, Otsubo H, Usui N, Yoshida M, Tanno J, Kurihara E, Matsumoto K, Hirata R, Domitsu K, Kobayashi M: Platelet size deviation width, platelet large cell ratio, and mean platelet volume have sufficient sensitivity and specificity in the diagnosis of immune thrombocytopenia. Br J Haematol 2005;128:698–702.
60.
Gohda F, Uchiumi H, Handa H, Matsushima T, Tsukamoto N, Morita K, Amagai H, Murakami M, Murakami H, Nojima Y, Karasawa M: Identification of inherited macrothrombocytopenias based on mean platelet volume among patients diagnosed with idiopathic thrombocytopenia. Thromb Res 2007;119:741–746.
61.
Kuwana M, Kurata Y, Fujimura K, Fujisawa K, Wada H, Nagasawa T, Nomura S, Kojima T, Yagi H, Ikeda Y: Preliminary laboratory-based diagnostic criteria for immune thrombocytopenic purpura: evaluation by multi-center prospective study. J Thromb Haemost 2006;4:1936–1943.
62.
Kuwana M, Okazaki Y, Satoh T, Asahi A, Kajihara M, Ikeda Y: Initial laboratory findings useful for predicting the diagnosis of idiopathic thrombocytopenic purpura. Am J Med 2005;118:1026–1033.
63.
Raife TJ, Olson JD, Lentz SR: Platelet antibody testing in idiopathic thrombocytopenic purpura. Blood 1997;89:1112–1114.
64.
Berchtold P, Müller D, Beardsley D, Fujisawa K, Kaplan C, Kekomäki R, Lipp E, Morell-Kopp MC, Kiefel V, McMillan R, von dem Borne AE, Imbach P: International study to compare antigen-specific methods used for the measurement of antiplatelet autoantibodies. Br J Haematol 1997;96:477–483.
65.
Brighton TA, Evans S, Castaldi PA, Chesterman CN, Chong BH: Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood 1996;88:194–201.
66.
Warner MN, Moore JC, Warkentin TE, Santos AV, Kelton JG: A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura. Br J Haematol 1999;104:442–447.
67.
McMillan R: Antiplatelet antibodies in chronic adult immune thrombocytopenic purpura: assays and epitopes. J Pediatr Hematol Oncol 2003;25(suppl 1):S57–S61.
68.
McMillan R, Wang L, Tani P: Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP). J Thromb Haemost 2003;1:485–491.
69.
Tarantino MD: Treatment options for chronic immune (idiopathic) thrombocytopenia purpura in children. Semin Hematol 2000;37(suppl 1):35–41.
70.
George JN: Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost 2006;4:1664–1672.
71.
Chandra J, Ravi R, Singh V, Narayan S, Sharma S, Dutta AK: Bleeding manifestations in severely thrombocytopenic children with immune thrombocytopenic purpura. Hematology 2006;11:131–133.
72.
Bolton-Maggs P: Severe bleeding in idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2003;25(suppl 1):S47–S51.
73.
George JN, Kojouri K, Perdue JJ, Vesely SK: Management of patients with chronic, refractory idiopathic thrombocytopenic purpura. Semin Hematol 2000;37:290–298.
74.
Lilleyman JS: Management of childhood idiopathic thrombocytopenic purpura. Br J Haematol 1999;105:871–875.
75.
Medeiros D, Buchanan GR: Major hemorrhage in children with idiopathic thrombocytopenic purpura: immediate response to therapy and long-term outcome. J Pediatr 1998;133:334–339.
76.
British Committee for Standards in Haematology General Haematology Task Force: Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003;120:574–596.
77.
George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, Blanchette VS, Bussel JB, Cines DB, Kelton JG, Lichtin AE, McMillan R, Okerbloom JA, Regan DH, Warrier I: Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3–40.
78.
Buchanan GR, Journeycake JM, Adix L: Severe chronic idiopathic thrombocytopenic purpura during childhood: definition, management, and prognosis. Semin Thromb Hemost 2003;29:595–603.
79.
Buchanan GR: Bleeding signs in children with idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2003;25(suppl 1):S42–S46.
80.
Buchanan GR, Adix L: Current challenges in the management of children with idiopathic thrombocytopenic purpura. Pediatr Blood Cancer 2006;47(5 suppl):681–684.
81.
Wandt H, Frank M, Ehninger G, Schneider C, Brack N, Daoud A, Fackler-Schwalbe I, Fischer J, Gackle R, Geer T, Harms P, Loffler B, Ohl S, Otremba B, Raab M, Schonrock-Nabulsi P, Strobel G, Winter R, Link H: Safety and cost effectiveness of a 10 × 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 1998;91:3601–3606.
82.
Peng J, Friese P, Heilmann E, George JN, Burstein SA, Dale GL: Aged platelets have an impaired response to thrombin as quantitated by P-selectin expression. Blood 1994;83:161–166.
83.
Blanchette VS, Price V: Childhood chronic immune thrombocytopenic purpura: unresolved issues. J Pediatr Hematol Oncol 2003;25(suppl 1):S28–S33
84.
Blanchette V: Childhood chronic immune thrombocytopenic purpura (ITP). Blood Rev 2002;16:23–26.
85.
Andersen JC: Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med 1994;330:1560–1564.
86.
Adams DM, Kinney TR, O’Branski-Rupp E, Ware RE: High-dose oral dexamethasone therapy for chronic childhood idiopathic thrombocytopenic purpura. J Pediatr 1996;128:281–283.
87.
Kühne T, Freedman J, Semple JW, Doyle J, Butchart S, Blanchette VS: Platelet and immune responses to oral cyclic dexamethasone therapy in childhood chronic immune thrombocytopenic purpura. J Pediatr 1997;130:17–24.
88.
Chen JS, Wu JM, Chen YJ, Yeh TF: Pulsed high-dose dexamethasone therapy in children with chronic idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 1997;19:526–529.
89.
Wali YA, Al Lamki Z, Shah W, Zacharia M, Hassan A: Pulsed high-dose dexamethasone therapy in children with chronic idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol 2002;19:329–335.
90.
Hedlund-Treutiger I, Henter JI, Elinder GJ: Randomized study of IVIg and high-dose dexamethasone therapy for children with chronic idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2003;25:139–144.
91.
Van Riet FA, Wessels G, Hesseling PB: Experience with high dose dexamethasone in the treatment of chronic symptomatic immune thrombocytopaenia. East Afr Med J 1999;76:571–574.
92.
Eskenazi AE, Louie J: Transient response to multiple courses of pulse high-dose dexamethasone therapy in children with idiopathic thrombocytopenic purpura. Haematologia (Budap) 1998;29:81–87.
93.
Demiroglu H, Dundar S: High-dose pulsed dexamethasone for immune thrombocytopenia. N Engl J Med 1997;337:425–427.
94.
Stasi R, Brunetti M, Pagano A, Stipa E, Masi M, Amadori S: Pulsed intravenous high-dose dexamethasone in adults with chronic idiopathic thrombocytopenic purpura. Blood Cells Mol Dis 2000;26:582–586.
95.
Ozer EA, Yaprak I, Atabay B, Turker M, Aksit S, Sarioglu B: Oral cyclic megadose methylprednisolone therapy for chronic immune thrombocytopenic purpura in childhood. Eur J Haematol 2000;64:411–415.
96.
Altintop L, Albayrak D: Oral high-dose methylprednisolone and intravenous immunoglobulin treatments in adult chronic idiopathic thrombocytopenic purpura. Am J Hematol 1997;56:191–192.
97.
Dilber C, Dagdemir A, Albayrak D, Albayrak S, Kalayci AG, Aliyazicioglu Y, Basoglu T: Reduced bone mineral density in childhood chronic idiopathic thrombocytopenic purpura treated with high-dose methylprednisolone. Bone 2004;35:306–311.
98.
El Alfy MS, Khalifa AS: Prospective evaluation of high-cost management of severe chronic ITP in children and adolescents <16 years. Pediatr Blood Cancer 2006;47(5 suppl):731–733.
99.
Blanchette V, Carcao M: Intravenous immunoglobulin G and anti-D as therapeutic interventions in immune thrombocytopenic purpura. Transfus Sci 1998;19:279–288.
100.
Blanchette VS, Luke B, Andrew M, Sommerville-Nielsen S, Barnard D, de Veber B, Gent M: A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr 1993;123:989–995.
101.
Blanchette V, Imbach P, Andrew M, Adams M, McMillan J, Wang E, Milner R, Ali K, Barnard D, Bernstein M, Chan KW, Esseltine D, deVeber B, Israels S, Kobrinsky N, Luke B: Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994;344:703–707.
102.
Bussel JB, Kimberly RP, Inman RD, Schulman I, Cunningham-Rundles C, Cheung N, Smithwick EM, O’Malley J, Barandun S, Hilgartner MW: Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood 1983;62:480–486.
103.
Bussel JB, Goldman A, Imbach P, Schulman I, Hilgartner MW: Treatment of acute idiopathic thrombocytopenia of childhood with intravenous infusions of gammaglobulin. J Pediatr 1985;106:886–890.
104.
Bussel JB, Schulman I, Hilgartner MW, Barandun S: Intravenous use of gammaglobulin in the treatment of chronic immune thrombocytopenic purpura as a means to defer splenectomy. J Pediatr 1983;103:651–654.
105.
Bierling P, Godeau B: Intravenous immunoglobulin and autoimmune thrombocytopenic purpura: 22 years on. Vox Sang 2004;86:8–14.
106.
Godeau B, Lesage S, Divine M, Wirquin V, Farcet JP, Bierling P: Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood 1993;82:1415–1421.
107.
Godeau B, Caulier MT, Decuypere L, Rose C, Schaeffer A, Bierling P: Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: results of a randomized trial comparing 0.5 and 1 g/kg b.w. Br J Haematol 1999;107:716–719.
108.
Warrier I, Bussel JB, Valdez L, Barbosa J, Beardsley DS: Safety and efficacy of low-dose intravenous immune globulin (IVIG) treatment for infants and children with immune thrombocytopenic purpura. Low-Dose IVIG Study Group. J Pediatr Hematol Oncol 1997;19:197–201.
109.
Kattamis AC, Shankar S, Cohen AR: Neurologic complications of treatment of childhood acute immune thrombocytopenic purpura with intravenously administered immunoglobulin G. J Pediatr 1997;130:281–283.
110.
Sati HI, Ahya R, Watson HG: Incidence and associations of acute renal failure complicating high-dose intravenous immunoglobulin therapy. Br J Haematol 2001;113:556–557.
111.
Sekul EA, Cupler EJ, Dalakas MC: Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994;121:259–262.
112.
Thomas MJ, Misbah SA, Chapel HM, Jones M, Elrington Ewsom-Davis J: Hemolysis after high-dose intravenous Ig. Blood 1993;82:3789.
113.
Jayabose S, Mahmoud M, Levendoglu-Tugal O, Sandoval C, Ozkaynak F, Giamelli J Jr, Visintainer P: Corticosteroid prophylaxis for neurologic complications of intravenous immunoglobulin G therapy in childhood immune thrombocytopenic purpura. J Pediatr Hematol Oncol 1999;21:514–517.
114.
Adams JR, Nathan DP, Bennett CL: Pharmacoeconomics of therapy for ITP: steroids, i.v. Ig, anti-D, and splenectomy. Blood Rev 2002;16:65–67.
115.
Kjaersgaard M, Hasle H: A review of anti-D treatment of childhood idiopathic thrombocytopenic purpura. Pediatr Blood Cancer 2006;47(5 suppl):717–720.
116.
El Alfy MS, Mokhtar GM, El-Laboudy MA, Khalifa AS: Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura. Acta Haematol 2006;115:46–52.
117.
Sajid R, Adil SN, Fadoo Z, Sabir S, Khurshid M: Use of intravenous anti-D in patients with refractory and relapsed immune thrombocytopenic purpura. J Pak Med Assoc 2003;53:537–539.
118.
Bussel JB, Graziano JN, Kimberly RP, Pahwa S, Aledort LM: Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood 1991;77:1884–1893.
119.
Andrew M, Blanchette VS, Adams M, Ali K, Barnard D, Chan KW, DeVeber LB, Esseltine D, Israels S, Korbrinsky N: A multicenter study of the treatment of childhood chronic idiopathic thrombocytopenic purpura with anti-D. J Pediatr 1992;120:522–527.
120.
Becker T, Kuenzlen E, Salama A, Mertens R, Kiefel V, Weiss H, Lampert F, Gaedicke G, Mueller-Eckhardt C: Treatment of childhood idiopathic thrombocytopenic purpura with Rhesus antibodies (anti-D). Eur J Pediatr 1986;145:166–169.
121.
Freiberg A, Mauger D: Efficacy, safety, and dose response of intravenous anti-D immune globulin (WinRho SDF) for the treatment of idiopathic thrombocytopenic purpura in children. Semin Hematol 1998;35(suppl 17):23–27.
122.
Scaradavou A, Woo B, Woloski BM, Cunningham-Rundles S, Ettinger LJ, Aledort LM, Bussel JB: Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 1997;89:2689–2700.
123.
Bennett CL, Weinberg PD, Golub RM, Bussel JB: The potential for treatment of idiopathic thrombocytopenic purpura with anti-D to prevent splenectomy: a predictive cost analysis. Semin Hematol 2000;37 (suppl 1):26–30.
124.
Cooper N, Woloski BM, Fodero EM, Novoa M, Leber M, Beer JH, Bussel JB: Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy? Blood 2002;99:1922–1927.
125.
Borgna-Pignatti C, Battisti L, Zecca M, Locatelli F: Treatment of chronic childhood immune thrombocytopenic purpura with intramuscular anti-D immunoglobulins. Br J Haematol 1994;88:618–620.
126.
Newman GC, Novoa MV, Fodero EM, Lesser ML, Woloski BM, Bussel JB: A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol 2001;112:1076–1078.
127.
Tarantino MD, Young G, Bertolone SJ, Kalinyak KA, Shafer FE, Kulkarni R, Weber LC, Davis ML, Lynn H, Nugent DJ, Acute ITP Study Group: Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. J Pediatr 2006;148:489–494.
128.
Ambriz-Fernandez R, Martinez-Murillo C, Quintana-Gonzalez S, Collazo-Jaloma J, Bautista-Juarez J: Fc receptor blockade in patients with refractory chronic immune thrombocytopenic purpura with anti-D IgG. Arch Med Res 2002;33:536–540.
129.
Ruiz-Arguelles GJ, Lopez-Martinez B, Flores-Martinez J, Ruiz-Arguelles A, Perez-Romano B: An affordable Fc-receptor blockade method to treat patients with chronic refractory autoimmune thrombocytopenic purpura. Haematologica 2001;86:552–553.
130.
Yaprak I, Caglayan S, Kansoy S, Ozdogru E, Bakiler AR, Aydinlioglu H: Long-term use of anti-D in chronic idiopathic thrombocytopenic purpura. Turk J Pediatr 1994;36:43–47.
131.
Krishnamurti L, Charan VD, Desai N, Pati H, Choudhry VP: Anti-D immunoglobulin in the treatment of idiopathic thrombocytopenic purpura. Indian J Pediatr 1994;61:179–182.
132.
Meyer O, Kiesewetter H, Hermsen M, Petriedes P, Rose M, Seibt H, Salama A: Replacement of intravenous administration of anti-D by subcutaneous administration in patients with autoimmune thrombocytopenia. Pediatr Blood Cancer 2006;47(5 suppl):721–722.
133.
Meyer O, Kiesewetter H, Hermsen M, Salama A: Efficacy and safety of anti-D given by subcutaneous injection to patients with autoimmune thrombocytopenia. Eur J Haematol 2004;73:71–72.
134.
Hong F, Ruiz R, Price H, Griffiths A, Malinoski F, Woloski M: Safety profile of WinRho anti-D. Semin Hematol 1998;35(suppl 1):9–13.
135.
Kees-Folts D, Abt AB, Domen RE, Freiberg AS: Renal failure after anti-D globulin treatment of idiopathic thrombocytopenic purpura. Pediatr Nephrol 2002;17:91–96.
136.
Gaines AR: Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(o)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Blood 2000;95:2523–2529.
137.
Gaines AR: Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 2005;106:1532–1537.
138.
Christopher K, Horkan C, Barb IT, Arbelaez C, Hodgdon TA, Yodice PC: Rapid irreversible encephalopathy associated with anti-D immune globulin treatment for idiopathic thrombocytopenic purpura. Am J Hematol 2004;77:299–302.
139.
Kojouri K, Vesely SK, Terrell DR, George JN: Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004;104:2623–2634.
140.
Ramenghi U, Amendola G, Farinasso L, Giordano P, Loffredo G, Nobili B, Perrotta S, Russo G, Zecca M: Splenectomy in children with chronic ITP: long-term efficacy and relation between its outcome and responses to previous treatments. Pediatr Blood Cancer 2006;47(5 suppl):742–745.
141.
Shad AT, Gonzalez CE, Sandler SG: Treatment of immune thrombocytopenic purpura in children: current concepts. Paediatr Drugs 2005;7:325–336.
142.
Mantadakis E, Buchanan G: Elective splenectomy in children with idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2000;22:148–153.
143.
Holt D, Brown J, Terrill K, Goldsby R, Meyers RL, Heximer J, Nordfors B, Slayton WB: Response to intravenous immunoglobulin predicts splenectomy response in children with immune thrombocytopenic purpura. Pediatrics 2003;111:87–90.
144.
El-Alfy MS, El-Tawil MM, Shahein N: 5- to 16-year follow-up following splenectomy in chronic immune thrombocytopenic purpura in children. Acta Haematol 2003;110:20–24.
145.
Aronis S, Platokouki H, Avgeri M, Pergantou H, Keramidas D: Retrospective evaluation of long-term efficacy and safety of splenectomy in chronic idiopathic thrombocytopenic purpura in children. Acta Paediatr 2004;93:638–642.
146.
Vianelli N, Galli M, De Vivo A, Intermesoli T, Giannini B, Mazzucconi MG, Barbui T, Tura S, Baccaranion M, Gruppo Italiano per lo Studio delle Malattie Ematologiche dell’Adulto: Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica 2005;90:72–77.
147.
Wang T, Xu M, Ji L, Yang R: Splenectomy for chronic idiopathic thrombocytopenic purpura in children: a single center study in China. Acta Haematol 2006;115:39–45.
148.
Kühne T, Blanchette V, Buchanan GR, Ramenghi U, Donato H, Tamminga RY, Rischewski J, Berchtold W, Imbach P, Intercontinental Childhood ITP Study Group: Splenectomy in children with idiopathic thrombocytopenic purpura: a prospective study of 134 children from the Intercontinental Childhood ITP Study Group. Pediatr Blood Cancer 2007;49:829–834.
149.
Law C, Marcaccio M, Tam P, Heddle N, Kelton JG: High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura. N Engl J Med 1997;336:1494–1498.
150.
Hemmila MR, Foley DS, Castle VP, Hirschl RB: The response to splenectomy in pediatric patients with idiopathic thrombocytopenic purpura who fail high-dose intravenous immune globulin. J Pediatr Surg 2000;35:967–971; discussion 971–972.
151.
Choi CW, Kim BS, Seo JH, Shin SW, Kim YH, Kim JS, Sohn SK, Kim JS, Shin DG, Ryoo HM, Lee KH, Lee JJ, Chung IJ, Kim HJ, Kwak JY, Yim CY, Ahn JS, Lee JA, Park YS: Response to high-dose intravenous immune globulin as a valuable factor predicting the effect of splenectomy in chronic idiopathic thrombocytopenic purpura patients. Am J Hematol 2001;66:197–202.
152.
Schneider P, Wehmeier A, Schneider W: High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura. N Engl J Med 1997;337:1087–1088.
153.
Fabris F, Cordiano I, Girolami A: High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura. N Engl J Med 1997;337:1088–1089.
154.
Ruivard M, Caulier MT, Vantelon JM, Tournilhac O, Schaeffer A, Godeau B, Bierling P: The response to high-dose intravenous immunoglobulin or steroids is not predictive of outcome after splenectomy in adults with autoimmune thrombocytopenic purpura. Br J Haematol 1999;105:1130–1132.
155.
Bussel JB, Kaufmann CP, Ware RE, Woloski BM: Do the acute platelet responses of patients with immune thrombocytopenic purpura (ITP) to IV anti-D and to IV gammaglobulin predict response to subsequent splenectomy? Am J Hematol 2001;67:27–33.
156.
Radaelli F, Faccini P, Goldaniga M, Guggiari E, Pozzoli E, Maiolo AT, Ciani A, Pogliani EM: Factors predicting response to splenectomy in adult patients with idiopathic thrombocytopenic purpura. Haematologica 2000;85:1040–1044.
157.
Kumar S, Diehn FE, Gertz MA, Tefferi A: Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses. Ann Hematol 2002;81:312–319.
158.
Castagnola E, Fioredda F: Prevention of life-threatening infections due to encapsulated bacteria in children with hyposplenia or asplenia : a brief review of current recommendations for practical purposes. Eur J Haematol 2003;71:319–326.
159.
Davies JM, Barnes R, Milligan D: British Committee for Standards in Haematology. Working Party of the Haematology/Oncology Task Force. Update of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. Clin Med 2002;2:440–443.
160.
Waghorn DJ: Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed. J Clin Pathol 2001;54:214–218.
161.
Bisharat N, Omari H, Lavi I, Raz R: Risk of infection and death among post-splenectomy patients. J Infect 2001;43:182–186.
162.
Brigden ML: Detection, education and management of the asplenic or hyposplenic patient. Am Fam Physician 2001;63:499–506, 508.
163.
Wilson B: Acquired platelet defects; in Orkin SH, Nathan DG, Ginsburg D, Look AT,. Fisher DE (eds): Nathan and Oski’s Hematology of Infancy and Childhood, ed 6. Philadelphia, Saunders, 2003, pp 1605–1609.
164.
British Committee for Standards in Haematology, Blood Transfusion Task Force: Guidelines for the use of platelet transfusions. Br J Haematol 2003;122:10–23.
165.
Barnes C, Blanchette V, Canning P, Carcao M: Recombinant FVIIa in the management of intracerebral haemorrhage in severe thrombocytopenia unresponsive to platelet-enhancing treatment. Transfus Med 2005;15:145–150.
166.
Savani BN, Dunbar CE, Rick ME: Combination therapy with rFVIIa and platelets for hemorrhage in patients with severe thrombocytopenia and alloimmunization. Am J Hematol 2006;81:218–219.
167.
Mathew P: The use of rFVIIa in non-haemophilia bleeding conditions in paediatrics. A systematic review. Thromb Haemost 2004;92:738–746.
168.
Bolton-Maggs P: The management of immune thrombocytopenic purpura. Curr Paediatr 2002;12:298–303.
169.
Middleton PM: Epistaxis. Emerg Med Australas 2004;16:428–440.
170.
Kubba H: Childhood epistaxis. Clin Otolaryngol 2006;31:212–213.
171.
von Mackensen S, Nilsson C, Jankovic M, Mirra N, D’Angelo E, Borkhardt A, Ljung R: Development of a disease-specific quality of life questionnaire for children & adolescents with idiopathic thrombocytopenic purpura (ITP-QoL). Pediatr Blood Cancer 2006;47(5 suppl):688–691.
172.
Barnard D, Woloski M, Feeny D, McCusker P, Wu J, David M, Bussel J, Lusher J, Wakefield C, Henriques S, Blanchette V, Canadian Children’s Platelet Study Group: Development of disease-specific health-related quality-of-life instruments for children with immune thrombocytopenic purpura and their parents. J Pediatr Hematol Oncol 2003;25:56–62.
173.
Nakayama T, Onoda K: Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994 to 2004. Vaccine 2007;25:570–576.
174.
Neiderud J: Thrombocytopenic purpura after a combined vaccine against morbilli, parotitis and rubella. Acta Paediatr Scand 1983;72:613–614.
175.
Arya LS, Ghai OP, Saraya AK: Thrombocytopenic purpura following DTP vaccination. Pediatr Hematol Oncol 1993;10:381–383.
176.
Conesa V, Nuñez MF, Navarro JF, Mompel A, Ruiz J, Gómez A: Thrombocytopenic purpura after recombinant hepatitis B vaccine. A rare association. Haematologica 2001;86:E09.
177.
Miller E, Waight P, Farrington CP, Andrews N, Stowe J, Taylor B: Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 2001;84:227–229.
178.
American Academy of Pediatrics Committee on Infectious Diseases: 2006 Report of the Committee on Infectious Diseases. Red Book. Elk Grove Village, American Academy of Pediatrics, 2006, pp 847–851.
179.
Vlacha V, Forman EN, Miron D, Peter G: Recurrent thrombocytopenic purpura after repeated measles-mumps-rubella vaccination. Pediatrics 1996;97:738–739.
180.
Wang JD, Huang FL, Chen PY, Wang TM, Chi CS, Chang TK: Acute immune thrombocytopenic purpura in infants: associated factors, clinical features, treatment and long-term outcome. Eur J Haematol 2006;77:334–337.
181.
Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L: Measles, mumps and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practice (ACIP). MMWR Recomm Rep 1998;47:1–57.
182.
Centers for Diseases Control and Prevention: Recommendations of the Advisory Committee on Immunization Practises (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence. MMWR Recomm Rep 1993;42:1–18.
183.
Advisory Committee on Immunization Practices: Preventing pneumococcal disease among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000;49:1–35.
184.
Platelet Disorder Support Association (http://www.pdsa.org/itp-information/index.html).
185.
Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG: Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007;146:25–33.
186.
Parodi E, Nobili B, Perrotta S, Matarese SM, Russo G, Licciardello M, Zecca M, Locatelli F, Cesaro S, Bisogno G, Giordano P, De Mattia D, Ramenghi U: Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic ITP. Int J Hematol 2006;84:48–53.
187.
Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, Sawaf H, Moore TB, Loh ML, Glader BE, McCarthy MC, Mueller BU, Olson TA, Lorenzana AN, Mentzer WC, Buchanan GR, Feldman HA, Neufeld EJ: Prospective phase 1/2 study of rituximab in childhood and adolescent chronic ITP. Blood 2006;107:2639–2642.
188.
Wang J, Wiley JM, Luddy R, Greenberg J, Feuerstein MA, Bussel JB: Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr 2005;146:217–221.
189.
Taube T, Schmid H, Reinhard H, von Stackelberg A, Overberg US: Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. Haematologica 2005;90:281–283.
190.
Bay A, Oner AF, Uner A, Dogan M: Use of rituximab in chronic childhood immune thrombocytopenic purpura. Pediatr Int 2006;48:514–516.
191.
Roganovic J: Rituximab treatment in idiopathic thrombocytopenic purpura in children. Eur J Pediatr 2005;164:334.
192.
Russo G, Licciardello M, La Spina M: Rituximab in children with idiopathic chronic thrombocytopenic purpura: does it really work? Eur J Pediatr 2004;163:569.
193.
Pusiol A, Cesaro S, Nocerino A, Picco G, Zanesco L, Bisogno G: Successful treatment with the monoclonal antibody rituximab in two children with refractory autoimmune thrombocytopenia. Eur J Pediatr 2004;163:305–307.
194.
Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J, Wasser JS, Wiznitzer I, Kelly R, Chen CF, Nichol JL: AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006;355:1672–1681.
195.
Kuter D, Bussel JB, George J, Aledort L, Lichtin A, Lyons R, Nieva J, Wasser J, Bourgeois E, Kappers-Klunne M, Lefrere F, Schipperus M, Kelly R, Christal J, Guo M, Nichol J: Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytic purpura: 48 week update (abstract). Orlando, 48th Annu Meet Am Soc Hematol, 2006. Blood 2006;108(suppl): 476.
196.
Bussel JB, Cheng G, Saleh M, Kovaleva L, Stone N, Mayer B, Jenkins J, Provan A: Analysis of bleeding in patients with immune thrombocytopenic purpura (ITP): a randomized double blind, placebo-controlled trial of eltrombopag, an oral platelet growth factor. Orlando, 48th Annu Meet Am Soc Hematol, 2006. Blood 2006;108 (suppl):475.
197.
Provan D, Moss AJ, Newland AC, Bussel JB: Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am J Hematol 2006;81:19–25.
198.
Chang HK: Successful treatment of refractory thrombocytopenia with mycophenolate mofetil in a patient with systemic lupus erythematosus. J Korean Med Sci 2005;20:883–885.
199.
Kotb R, Pinganaud C, Trichet C, Lambotte O, Dreyfus M, Delfraissy JF, Tchernia G, Goujard C: Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur J Haematol 2005;75:60–64.
200.
Zhang WG, Ji L, Cao XM, Chen YX, He AL, Liu J, Zhao WH, Zou SP: Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenic purpura. Acta Pharmacol Sin 2005;26:598–602.
201.
Waldman MA, Callen JP: Mycophenolate mofetil treatment of a patient with hyperglobulinemic purpura. J Am Acad Dermatol 2004;51:667–669.
202.
Vasoo S, Thumboo J, Fong KY: Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil. Lupus 2003;12:630–632.
203.
Hou M, Peng J, Shi Y, Zhang C, Qin P, Zhao C, Ji X, Wang X, Zhang M: Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol 2003;70:353–357.
204.
Howard J, Hoffbrand AV, Prentice HG, Mehta A: Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. Br J Haematol 2002;117:712–715.
205.
Damodar S, Viswabandya A, George B, Mathews V, Chandy M, Srivastava A: Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults – a report on 90 patients. Eur J Haematol 2005;75:328–331.
206.
Alliot C, Barrios M: Efficacy of dapsone in an adolescent with chronic autoimmune thrombocytopenia. Therapie 2004;59:479–480.
207.
Meeker ND, Goldsby R, Terrill KR, Delaney KS, Slayton WB: Dapsone therapy for children with immune thrombocytopenic purpura. J Pediatr Hematol Oncol 2003;25:173–175.
208.
Dutta TK, Goel A, Ghotekar LH, Hamide A, Badhe BA, Basu D: Dapsone in treatment of chronic idiopathic thrombocytopenic purpura in adults. J Assoc Physicians India 2001;49:421–425.
209.
Lush R, Iland H, Peat B, Young G: Successful use of dapsone in refractory pregnancy-associated idiopathic thrombocytopenic purpura. Aust NZ J Med 2000;30:105–107.
210.
Le Louet H, Ruivart M, Bierling P, Duche JC, Godeau B: Lack of relevance of the acetylator status on dapsone response in chronic autoimmune thrombocytopenic purpura. Am J Hematol 1999;62:251–252.
211.
Radaelli F, Calori R, Goldaniga M, Guggiari E, Luciano A: Adult refractory chronic idiopathic thrombocytopenic purpura: can dapsone be proposed as second-line therapy? Br J Haematol 1999;104:641–642.
212.
Godeau B, Durand JM, Roudot-Thoraval F, Tenneze A, Oksenhendler E, Kaplanski G, Schaeffer A, Bierling P: Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases. Br J Haematol 1997;97:336–339.
213.
Hernandez F, Linares M, Colomina P, Pastor E, Cervero A, Perez A, Perella M: Dapsone for refractory chronic idiopathic thrombocytopenic purpura. Br J Haematol 1995;90:473–475.
214.
Linares M, Cervero A, Pastor E, Colomina P: Dapsone for idiopathic thrombocytopenic purpura. Am J Hematol 1994;46:371–372.
215.
Godeau B, Oksenhendler E, Bierling P: Dapsone for autoimmune thrombocytopenic purpura. Am J Hematol 1993;44:70–72.
216.
Durand JM, Lefevre P, Hovette P, Mongin M, Soubeyrand J: Dapsone for idiopathic autoimmune thrombocytopenic purpura in elderly patients. Br J Haematol 1991;78:459–460.
217.
Jim RT: Therapeutic use of dapsone in idiopathic thrombocytopenic purpura. Hawaii Med J 1989;48:279–280.
218.
Schiff DE, Roberts WD, Sue YJ: Methemoglobinemia associated with dapsone therapy in a child with pneumonia and chronic immune thrombocytopenic purpura. J Pediatr Hematol Oncol 2006;28:395–398.
219.
Ahn YS, Harrington WJ, Simon SR, Mylvaganam R, Pall LM, So AG: Danazol for the treatment of idiopathic thrombocytopenic purpura. N Engl J Med 1983;308:1396–1399.
220.
Weinblatt ME, Kochen J, Ortega J: Danazol for children with immune thrombocytopenic purpura. Am J Dis Child 1988;142:1317–1319.
221.
Quiquandon I, Fenaux P, Caulier MT, Pagniez D, Huart JJ, Bauters F: Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases. Br J Haematol 1990;74:223–228.
222.
Cines DB, Blanchette VS: Immune thrombocytopenic purpura. N Engl J Med 2002;346:995–1008.
223.
Figueroa M, Gehlsen J, Hammond D, Ondreyco S, Piro L, Pomeroy T, Williams F, McMillan R: Combination chemotherapy in refractory immune thrombocytopenic purpura. N Engl J Med 1993;328:1226–1229.
224.
Choudhry VP, Kashyap R, Ahlawat S, Pati HP: Vinblastine and danazol therapy in steroid resistant childhood chronic idiopathic thrombocytopenic purpura. Int J Hematol 1995;61:157–162.
225.
Reiner A, Gernsheimer T, Slichter SJ: Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood 1995;85:351–358.
226.
Wróbel G, Dobaczewski G, Patkowski D, Sokół A, Grotthus E: Experiences with recombinant activated factor VII in the treatment of severe refractory thrombocytopenia. Pediatr Blood Cancer 2006;47(5 suppl):729–730.
227.
Kessler C: Haemorrhagic complications of thrombocytopenia and oral anticoagulation: is there a role for recombinant activated factor VII? Intensive Care Med 2002;28(suppl 2):S228–S234.
228.
Perrotta S, Amendola G, Locatelli F, Conte ML, Rossi F, d’Urzo G, Nobili B: Treatment with short-term, high-dose cyclosporin A in children with refractory chronic idiopathic thrombocytopenic purpura. Br J Haematol 2003;121:143–147.
229.
Gesundheit B, Cividalli G, Freeman A, Yatziv S, Koren G, Baruchel S: Cyclosporin A in the treatment of refractory immune thrombocytopenia purpura in children. Eur J Haematol 2001;66:347–351.
230.
Moskowitz IP, Gaynon PS, Shahidi NT, Cripe TP: Low-dose cyclosporin A therapy in children with refractory immune thrombocytopenic purpura. J Pediatr Hematol Oncol 1999;21:77–79.
231.
Schultz KR, Strahlendorf C, Warrier I, Ravindranath Y: Cyclosporin A therapy of immune-mediated thrombocytopenia in children. Blood 1995;85:1406–1408.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.